CADL has 36-month beta value of -0.93. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CADL is 19.35M, and currently, short sellers hold a 8.73% ratio of that float. The average trading volume of CADL on September 19, 2024 was 371.79K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CADL) stock’s latest price update
Candel Therapeutics Inc (NASDAQ: CADL) has experienced a rise in its stock price by 10.39 compared to its previous closing price of 7.03. However, the company has seen a gain of 17.68% in its stock price over the last five trading days. seekingalpha.com reported 2024-07-29 that The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.
CADL’s Market Performance
CADL’s stock has risen by 17.68% in the past week, with a monthly rise of 47.71% and a quarterly rise of 15.40%. The volatility ratio for the week is 9.67% while the volatility levels for the last 30 days are 8.64% for Candel Therapeutics Inc The simple moving average for the past 20 days is 23.94% for CADL’s stock, with a 68.82% simple moving average for the past 200 days.
Analysts’ Opinion of CADL
Many brokerage firms have already submitted their reports for CADL stocks, with H.C. Wainwright repeating the rating for CADL by listing it as a “Buy.” The predicted price for CADL in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on December 02, 2022 of the previous year 2022.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see CADL reach a price target of $18. The rating they have provided for CADL stocks is “Outperform” according to the report published on November 19th, 2021.
UBS gave a rating of “Buy” to CADL, setting the target price at $9 in the report published on August 23rd of the previous year.
CADL Trading at 28.39% from the 50-Day Moving Average
After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.77% of loss for the given period.
Volatility was left at 8.64%, however, over the last 30 days, the volatility rate increased by 9.67%, as shares surge +47.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.08% upper at present.
During the last 5 trading sessions, CADL rose by +17.75%, which changed the moving average for the period of 200-days by +763.18% in comparison to the 20-day moving average, which settled at $6.38. In addition, Candel Therapeutics Inc saw 427.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CADL starting from Aguilar-Cordova Estuardo, who proposed sale 28,840 shares at the price of $6.50 back on Sep 13 ’24. After this action, Aguilar-Cordova Estuardo now owns shares of Candel Therapeutics Inc, valued at $187,460 using the latest closing price.
Tyagarajan Seshu, the Chief Technology Officer of Candel Therapeutics Inc, sale 14,851 shares at $6.47 during a trade that took place back on Jul 17 ’24, which means that Tyagarajan Seshu is holding 146,049 shares at $96,125 based on the most recent closing price.
Stock Fundamentals for CADL
Current profitability levels for the company are sitting at:
- -20.07 for the present operating margin
- 0.37 for the gross margin
The net margin for Candel Therapeutics Inc stands at -28.15. The total capital return value is set at -2.85. Equity return is now at value -480.68, with -117.35 for asset returns.
Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 2.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at -1.79. The interest coverage ratio of the stock is -29.29.
Currently, EBITDA for the company is -37.19 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 138.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.62.
Conclusion
To put it simply, Candel Therapeutics Inc (CADL) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
